Surgery Partners, Inc. Common Stock
Here’s whether Surgery Partners, Inc. Common Stock (SGRY) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+2.23% over 10 days); RSI 41 — healthy momentum range; 3-month momentum positive (+9.7%). Concerns: weak 1-year return of -25.1%. Currently 34.7% off its 52-week high. Score: +5/7.
SGRY is in a confirmed uptrend, trading above both its 50-day ($14.97) and 200-day ($15.57) moving averages. An RSI of 40.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -25.1% compares to +16.5% for SPY (trailed the market by 41.6%). The current 34.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.